[go: up one dir, main page]

SG170772A1 - Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide - Google Patents

Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Info

Publication number
SG170772A1
SG170772A1 SG201102150-8A SG2011021508A SG170772A1 SG 170772 A1 SG170772 A1 SG 170772A1 SG 2011021508 A SG2011021508 A SG 2011021508A SG 170772 A1 SG170772 A1 SG 170772A1
Authority
SG
Singapore
Prior art keywords
methyl
ylamino
imidazol
pyrimidin
pyridin
Prior art date
Application number
SG201102150-8A
Other languages
English (en)
Inventor
Paul W Manley
Wen-Chung Shieh
Paul Allen Sutton
Piotr H Karpinski
Raeann Wu
Stephanie Monnier
Joerg Brozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37398525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG170772(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG170772A1 publication Critical patent/SG170772A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG201102150-8A 2005-07-20 2006-07-18 Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide SG170772A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70140605P 2005-07-20 2005-07-20
US71621305P 2005-09-12 2005-09-12

Publications (1)

Publication Number Publication Date
SG170772A1 true SG170772A1 (en) 2011-05-30

Family

ID=37398525

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201102150-8A SG170772A1 (en) 2005-07-20 2006-07-18 Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Country Status (33)

Country Link
US (4) US8163904B2 (fr)
EP (2) EP2186808B1 (fr)
JP (1) JP5129132B2 (fr)
KR (3) KR20080027855A (fr)
CN (1) CN102267981A (fr)
AR (1) AR057467A1 (fr)
AT (1) ATE514689T1 (fr)
AU (2) AU2006276205C1 (fr)
BR (1) BRPI0613605A2 (fr)
CA (2) CA2615669C (fr)
CY (1) CY1111772T1 (fr)
DK (1) DK1910336T3 (fr)
EC (1) ECSP088118A (fr)
ES (1) ES2634291T3 (fr)
GT (1) GT200600316A (fr)
HR (1) HRP20110639T1 (fr)
IL (1) IL187787A (fr)
JO (1) JO2757B1 (fr)
MA (1) MA29686B1 (fr)
MX (1) MX2008000892A (fr)
MY (1) MY149889A (fr)
NO (1) NO341313B1 (fr)
NZ (2) NZ564182A (fr)
PE (1) PE20070241A1 (fr)
PL (1) PL1910336T3 (fr)
PT (1) PT1910336E (fr)
RU (4) RU2434864C2 (fr)
SG (1) SG170772A1 (fr)
SI (1) SI1910336T1 (fr)
TN (1) TNSN08028A1 (fr)
TW (1) TWI455934B (fr)
UY (1) UY29683A1 (fr)
WO (1) WO2007015871A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
RU2008143703A (ru) * 2006-04-07 2010-05-20 Новартис АГ (CH) ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА
EP1923053A1 (fr) * 2006-09-27 2008-05-21 Novartis AG Composition pharmaceutique comprenant de la nilotinib ou son sel
US20100016590A1 (en) 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
DK2262793T3 (da) 2008-11-05 2012-10-15 Teva Pharma Krystallinske former af nilotinib-hci
EP2186514B1 (fr) 2008-11-14 2016-06-29 Kinki University Traitement de tumeurs malignes de la gaine des nerfs périphériques
KR20110132439A (ko) 2009-03-06 2011-12-07 노파르티스 아게 류신 지퍼- 및 스테릴 알파 모티프-함유 키나제 （ｚａｋ）에 의해 매개된 장애의 치료를 위한 피리미딜아미노벤즈아미드 유도체의 용도
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
WO2011033307A1 (fr) 2009-09-17 2011-03-24 Generics [Uk] Limited Sel de dichlorhydrate de nilotinib
BR112012009094A8 (pt) 2009-10-23 2017-10-10 Novartis Ag método de tratamento de transtornos proliferativos e outras condições patológicas mediadas por bcr-abl, c-kit, ddr1,ddr2 ou atividade pdgf-r quinase
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2011086541A1 (fr) 2010-01-15 2011-07-21 Generics [Uk] Limited Nouveau polymorphe de monochlorhydrate de nilotinib monohydraté
WO2011128434A2 (fr) 2010-04-16 2011-10-20 Novartis Ag Traitement du cancer du sein hormono-résistant
EP2382976A1 (fr) 2010-04-30 2011-11-02 Hiroshima University Utilisation d'inhibiteurs pdgf-r pour le traitement de métastases dans les ganglions lymphatiques du cancer gastrique
JP5894153B2 (ja) * 2010-06-21 2016-03-23 テバ ファーマシューティカル インダストリーズ リミティド ニロチニブ塩及びそれらの結晶性形態
WO2012014127A1 (fr) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Inhibiteurs de 5-lipoxygénase
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
WO2012070062A2 (fr) * 2010-11-26 2012-05-31 Hetero Research Foundation Nouveau polymorphe de chlorhydrate de nilotinib
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013063003A1 (fr) 2011-10-28 2013-05-02 Novartis Ag Méthode de traitement des tumeurs stromales gastro-intestinales
US20140288073A1 (en) 2011-10-28 2014-09-25 Novartis Ag Method of Treating Gastrointestinal Stromal Tumors
KR20140093230A (ko) 2011-11-14 2014-07-25 노파르티스 아게 즉시 방출 4-메틸-3-[[4-(3-피리디닐)-2-피리미디닐]아미노]-n-[5-(4-메틸-1h-이미다졸-1-일)-3-(트리플루오로메틸)페닐] 벤즈아미드 제제
RU2015104537A (ru) 2012-07-11 2016-08-27 Новартис Аг Способы лечения стромальных опухолей желудочно-кишечного тракта
US9376419B2 (en) 2012-10-15 2016-06-28 Apotex Inc. Solid forms of nilotinib hydrochloride
WO2014060449A1 (fr) * 2012-10-19 2014-04-24 Basf Se Système cristallin multicomposant comprenant du nilotinib et des formateurs de co-cristal sélectionnés
EP2792360A1 (fr) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV
EA201592032A1 (ru) 2013-04-24 2016-04-29 Др. Реддис Лабораторис Лимитед Полиморфные формы гидрохлорида нилотиниба
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (fr) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Mono-oxalate de nilotinib et sa forme cristalline
US9926296B2 (en) 2014-08-08 2018-03-27 Dr. Reddy's Laboratories Limited Process for the preparation of polymorphic forms of nilotinib hydrochloride
LT3189045T (lt) * 2014-08-11 2022-04-11 Sun Pharmaceutical Industries Limited Naujos nilotinibo druskos ir jų polimorfai
US10301282B2 (en) 2015-03-20 2019-05-28 Cipla Limited Polymorphic form X of nilotinib dihydrochloride hydrate
SI3408264T1 (sl) 2016-01-26 2020-07-31 Farma Grs, D.O.O. Nilotinibijev dinitrat (V) in njegove kristalne oblike
WO2017149550A1 (fr) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Forme amorphe du 4-méthyl-n-[3-(4-méthyl-1h-imidazol-1-yl)-5-(trifluorométhyl)phényl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
US10640487B2 (en) 2016-03-14 2020-05-05 Teva Pharmaceuticals Usa, Inc. Solid state forms of Nilotinib salts
EP3404025B1 (fr) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Procede de preparation de nilotinib pur et de son sel
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
WO2020095187A1 (fr) * 2018-11-05 2020-05-14 Laurus Labs Limited Forme cristalline de chlorhydrate de nilotinib, son procédé de préparation et composition pharmaceutique le contenant
EP4509123A3 (fr) 2019-02-18 2025-05-07 Slayback Pharma LLC Composition pharmaceutique du nilotinib
JP2023513045A (ja) 2020-01-31 2023-03-30 ナノコピーア リミテッド ライアビリティ カンパニー 非晶質ニロチニブ微粒子及びその使用
US20230075170A1 (en) * 2020-02-15 2023-03-09 Cipla Limited Novel salts of nilotinib and polymorphic forms thereof
IL297776A (en) 2020-04-30 2022-12-01 Nanocopoeia Llc Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
JP2023543815A (ja) 2020-09-29 2023-10-18 シェンチェン ファーマシン シーオー．，エルティーディー． 医薬組成物
EP4260848A1 (fr) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Composition pharmaceutique pour forme posologique solide contenant du nilotinib et son procédé de préparation
LU103368B1 (en) 2022-12-29 2024-11-04 Renata Pharmaceuticals Ireland Ltd Pharmaceutical suspension of nilotinib

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2081108C1 (ru) * 1991-10-16 1997-06-10 Циба-Гейги АГ Аддитивные соли кислот с основанием и фармацевтическая композиция, обладающая противоопухолевой активностью
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1995009853A1 (fr) 1993-10-01 1995-04-13 Ciba-Geigy Ag Derives pyridine pharmacologiquement actifs ainsi que leurs procedes de preparation
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ATE362915T1 (de) * 1999-12-14 2007-06-15 Nippon Shinyaku Co Ltd Heterocyclische derivate und arzneistoffe
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
PE20051096A1 (es) * 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
SA06270147B1 (ar) * 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
NZ564182A (en) 2011-03-31
MX2008000892A (es) 2008-03-18
GT200600316A (es) 2007-04-02
RU2008105827A (ru) 2009-08-27
KR101755137B1 (ko) 2017-07-06
PL1910336T3 (pl) 2011-11-30
SI1910336T1 (sl) 2011-10-28
NO20080897L (no) 2008-02-20
US8163904B2 (en) 2012-04-24
AU2006276205C1 (en) 2024-08-01
EP2186808A1 (fr) 2010-05-19
KR20150100946A (ko) 2015-09-02
NO341313B1 (no) 2017-10-09
PT1910336E (pt) 2011-09-05
KR20080027855A (ko) 2008-03-28
CA2615669C (fr) 2013-11-12
TNSN08028A1 (en) 2009-07-14
US20120270891A1 (en) 2012-10-25
TW200800950A (en) 2008-01-01
IL187787A0 (en) 2008-08-07
US20130137712A1 (en) 2013-05-30
IL187787A (en) 2012-07-31
WO2007015871A1 (fr) 2007-02-08
AU2010241419C1 (en) 2024-05-23
RU2013101749A (ru) 2014-07-27
RU2434864C2 (ru) 2011-11-27
RU2605551C2 (ru) 2016-12-20
TWI455934B (zh) 2014-10-11
JO2757B1 (en) 2014-03-15
MA29686B1 (fr) 2008-08-01
US20140038994A1 (en) 2014-02-06
RU2509767C1 (ru) 2014-03-20
US8580806B2 (en) 2013-11-12
BRPI0613605A2 (pt) 2011-01-18
PE20070241A1 (es) 2007-03-22
UY29683A1 (es) 2007-02-28
DK1910336T3 (da) 2011-10-03
NZ591142A (en) 2012-09-28
AU2010241419B2 (en) 2012-03-29
KR20140047737A (ko) 2014-04-22
EP1910336B1 (fr) 2011-06-29
MY149889A (en) 2013-10-31
CN102267981A (zh) 2011-12-07
AU2006276205A1 (en) 2007-02-08
CA2615669A1 (fr) 2007-02-08
RU2011120363A (ru) 2012-11-27
AU2010241419A1 (en) 2010-12-02
JP2009502796A (ja) 2009-01-29
CY1111772T1 (el) 2015-10-07
CA2823946A1 (fr) 2007-02-08
JP5129132B2 (ja) 2013-01-23
HRP20110639T1 (hr) 2011-10-31
ECSP088118A (es) 2008-02-20
ATE514689T1 (de) 2011-07-15
US9163005B2 (en) 2015-10-20
US8389537B2 (en) 2013-03-05
AR057467A1 (es) 2007-12-05
EP2186808B1 (fr) 2017-04-19
US20080200487A1 (en) 2008-08-21
HK1116778A1 (en) 2009-01-02
EP1910336A1 (fr) 2008-04-16
RU2483065C2 (ru) 2013-05-27
CA2823946C (fr) 2015-12-29
AU2006276205B2 (en) 2010-08-19
ES2634291T3 (es) 2017-09-27

Similar Documents

Publication Publication Date Title
SG170772A1 (en) Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
PH12013501590A1 (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
TW200732295A (en) Selective N-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
ZA200710799B (en) Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
ZA200710457B (en) Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoro-methyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
TW200700423A (en) Heterobicyclic acrylamides
DK1835912T3 (da) Substituerede benzimidazoler til behandling af histomoniasis
UY3515Q (es) Parte superior inhalador-rotahaler-m-top